@entity10055 for XXXX .

@entity1 @entity409 @entity3851 @entity74 @entity1575 @entity204 @entity1577 @entity10055
BACKGROUND: Abnormal biliary secretion leads to the thickening of bile and the formation of plugs within the bile ducts; the consequent obstruction and abnormal bile flow ultimately results in the development of @entity1575 . This condition peaks in adolescence with up to 20% of adolescents with @entity1577 developing @entity409 . Early changes in the liver may ultimately result in @entity3851 with @entity1 needing transplantation. One therapeutic option currently used is @entity10055 . OBJECTIVES: To analyse evidence that @entity10055 improves indices of liver function, reduces the risk of developing @entity409 and improves outcomes in general in @entity1577 . SEARCH METHODS: We searched the Cochrane @entity1577 and @entity74 Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We also contacted drug companies.Date of the most recent search of the Group's trials register: 29 May 2014. SELECTION CRITERIA: Randomised controlled trials of the use of @entity10055 for at least three months compared with placebo or no additional treatment in @entity1 with @entity1577 . DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial eligibility and quality. MAIN RESULTS: Ten trials have been identified, of which three trials involving 118 @entity1 were included; the dose of @entity10055 ranged from 10 to 20 mg/kg/day for up to 12 months. The complex design used in two trials meant that data could only be analysed for subsets of @entity1 . There was no significant difference in weight change, mean difference -0.90 kg (95% confidence interval -1.94 to 0.14) based on 30 @entity1 from two trials. Improvement in biliary excretion was reported in only one trial and no significant change after treatment was shown. There were no data available for analysis for long-term outcomes such as @entity204 or need for liver transplantation. AUTHORS' CONCLUSIONS: There are few trials assessing the effectiveness of @entity10055 . There is insufficient evidence to justify its routine use in @entity1577 .
